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Abstract
Background: The current study was undertaken to examine total hospital costs per patient of a consecutive
implantation series of two 3rd generation Left Ventricle Assist Devices (LVAD). Further we analyzed if increased
clinical experience would reduce total hospital costs and the gap between costs and the diagnosis related grouped
(DRG)-reimbursement.
Method: Cost data of 20 LVAD implantations (VentrAssist™) from 2005-2009 (period 1) were analyzed together with
costs from nine patients using another LVAD (HeartWare™) from 2009-June 2011 (period 2). For each patient, total
costs were calculated for three phases - the pre-LVAD implantation phase, the LVAD implantation phase and the
post LVAD implant phase. Patient specific costs were obtained prospectively from patient records and included
personnel resources, medication, blood products, blood chemistry and microbiology, imaging and procedure costs
including operating room costs. Overhead costs were registered retrospectively and allocated to the specific patient
by predefined allocation keys. Finally, patient specific costs and overhead costs were aggregated into total hospital
costs for each patient. All costs were calculated in 2011-prices. We used regression analyses to analyze cost
variations over time and between the different devices.
Results: The average total hospital cost per patient for the pre-LVAD, LVAD and post-LVAD for period 1 was $ 585,
513 (range 132, 640- 1 247, 299), and the corresponding DRG- reimbursement (2009) was $ 143, 192 . The mean
LOS was 54 days (range 12- 127). For period 2 the total hospital cost per patient was $ 413, 185 (range 314,
540- 622, 664) and the corresponding DRG- reimbursement (2010) was $ 136, 963. The mean LOS was 49 days
(range 31- 93).
The estimates from the regression analysis showed that the total hospital costs, excluding device costs, per patient
were falling as the number of treated patients increased. The estimate from the trend variable was -14, 096 US$
(CI -3, 842 to -24, 349, p < 0.01).
Conclusion: There were significant reductions in total hospital costs per patient as the numbers of patients were
increasing. This can possibly be explained by a learning effect including better logistics, selection and management
of patients.
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Background
Prevalence of heart failure has been increasing over the
last decade and left ventricular assist device (LVAD)
therapy has to an increasing degree become an option
for patients in end-stage heart failure and also as an al-
ternative to heart transplant (Htx). There are currently a
variety of LVAD systems available, with different tech-
nology [1-4].
The aim of this study was to investigate how total hos-
pital costs per patient developed as the number of LVAD
procedures increased and clinical experience was accumu-
lated. The data consisted of information of patients from
two subsequent periods where two different 3rd generation
LVADs were used; in period 1 VentrAssist™LVAD
(removed from the market in 2008) and in period 2 Heart-
Ware™ LVAD (Framingham, MA, USA). Costs of the pre-
LVAD work-up and treatment, the LVAD implantation
phase as well as the post-LVAD care were evaluated in a
setting of implementation of a new treatment program.
Methods
Patient material and treatment procedure
We have earlier published a cost analysis with data from
our first nine VentrAssist™ LVAD implantations [5]. In
this paper we expand the analysis to include 11 further
implantations with VentrAssist™ LVAD from 2005-2009
(period 1) and nine consecutive implantations with
HeartWare™ LVADs from 2009 to June 2011 (period 2).
The cohort was recruited from patients evaluated for
Htx. Two patients receiving biventricular implants were
excluded from this analysis.
The normal pathway for LVAD patients was: 1) A pre-
LVAD period where the patients were admitted to the
Medical intensive care unit (MICU) for clinical evalu-
ation, investigation per protocol and treatment. Seven
patients were on Extracorporeal Membrane Oxygenation
(ECMO), while most of the patients were on intra-aortic
balloon pump (IABP) prior to the LVAD implantation.
2) A LVAD-phase including LVAD- surgical implant-
ation, stay in the Thorax intensive care unit (TICU) and
general ward. 3) The late post-LVAD course which
started at the date of discharge and went on to either
one year after implantation, date of Htx (if Htx was
within one year after discharge) or death within the first
year after implantation.
Cost analysis
The analysis involved two sets of data, one based on data
from the individual patient (direct costs) and one based
on overhead costs (indirect costs), with the overhead
costs ultimately also allocated to the individual patient.
The basic principle of the analysis was to relate as much
as possible of the resources used as direct costs to the
individual patient. A detailed description of costing
method is described in the previous article [5].
To compare cost between years all cost data were cal-
culated in 2011-prices using the price index for public
service production as deflator. We converted Norwegian
Kroner (NOK) to US dollars with the exchange rate of 1
US $= 5.80 NOK.
Statistical methods
We evaluated trends in total hospital costs per patients
and total hospital costs, excluding device costs, per pa-
tient by the means of multivariate regression analyses.
Initial testing indicated that the best model fit was
achieved by linear regression models. Two different spe-
cifications were estimated for each of the two dependent
variables. Due to few degrees of freedom (few cases) the
number of independent variables will be strongly limited.
Both specifications included number of patients and
days on ECMO. Number of patients worked as a trend
variable and was simply described as a variable taking
the value of 1 for the first LVAD-procedure and increas-
ing by 1 for each consecutive treatment. Days on ECMO
was entered to control for high risk patients. Addition-
ally, we included a variable describing type of LVAD in
one of the specifications. Type of LVAD was described
by a dummy variable HeartWare™= 1 (Additional file 1:
Appendix A). We considered P-values <0.05 as statisti-
cally significant and used SPSS 8 for all statistical
analyses.
DRG reimbursement
The actual DRG code for each patient is automatically
created by a combination of ICD-10 diagnosis and pro-
cedure code based on the Nordic Classification of Surgi-
cal Procedures (NOMESCO) [6,7]. In Norway, no
specific DRG for LVAD implantation existed at the time
of this study. So far all patients treated with extra-, para-
or intra-corporeal blood pumps (excluding IABP) had
been classified as a cardiac implantation with a mechan-
ical device and grouped with same DRG as Htx
(DRG103). “Htx” had in 2009 a unit price of $ 143, 192
and in 2010 $ 136, 963. If the patient had both LVAD
and Htx during the same hospital admission, only one
DRG 103 was assigned. There are no revenues coming
from out-of-pocket payment as in-patient stays are free
of charge in Norway [8].
Results
Among the 29 patients, 26 were men and three were fe-
male. Average age was 41 years (range 10- 72) at the time
of inclusion. At the termination of our project 22 patients
had received Htx, including one that had Htx during the
LVAD-stay, but who died after the Htx-procedure. Four
patients died without Htx, and three were still on device
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as outpatients. The mean length of hospital stay (LOS) for
the three phases was 52 days (range 12-127), of which
18 days (range 5-56) was in the ICU (Table 1).
Disaggregating the total costs for first 20 patients using
VentrAssist™LVADs into the different phases revealed
that the mean costs for the pre-LVAD phase were $ 186,
467 (range 6, 000- 586, 421) (Table 2). The major cost dri-
vers in this phase were personnel cost (63%) and ECMO-
procedure cost (23%) (Figure 1). The mean LOS in the
pre-LVAD phase was 15 days (range 1- 49). In the LVAD-
phase mean costs were $ 378, 450 (range 41, 957- 696,
483). The major cost drivers in this phase were personnel
costs (52%) and device costs (32%). The mean LOS for the
LVAD phase was 39 days (range 4- 125).
For the subsequent nine patients using the new device
(HeartWare™) the mean costs for the pre-LVAD phase
Table 1 Patients characteristics, LOS and endpoints
Pre-LVAD phase days) LVAD phase (days) Total in-hospital stay (days) End point
Patient # Age (years) Sex LOS ECMO LOS LOS LOS ICU LOS
VA 1 64 M 20 22 25 42 Htx
VA 2 62 M 1 26 7 27 †
VA 3 15 F 8 26 6 34 Htx
VA 4 38 M 5 6 28 27 33 Htx
VA 5 23 M 8 32 10 40 Htx
VA 6 54 M 1 14 26 18 27 Htx †
VA 7 65 M 8 29 11 37 *
VA 8 16 F 15 23 42 13 57 *
VA 9 20 M 13 21 5 34 Htx
VA 10 59 M 14 88 35 102 †
VA 11 55 M 8 39 39 47 †
VA 12 53 F 12 32 21 44 Htx
VA 13 10 M 6 39 14 45 Htx
VA 14 19 M 49 42 17 91 Htx
VA 15 27 M 39 11 56 18 95 Htx
VA 16 29 M 2 125 56 127 Htx
VA 17 32 M 32 45 23 77 Htx
VA 18 21 M 44 25 14 69 Htx
VA 19 61 M 1 40 12 41 Htx
VA 20 16 M 8 4 4 12 12 Htx
HW 1 39 M 0 3 41 15 41 Htx
HW 2 72 M 5 42 21 47 Htx
HW 3 56 M 29 29 8 58 *
HW 4 62 F 11 31 12 42 †
HW 5 54 M 36 57 40 93 Htx
HW 7 61 M 6 7 27 9 33 Htx
HW 8 26 M 12 19 7 31 Htx
HW 10 35 M 17 40 6 57 Htx
HW 11 46 M 6 30 13 36 Htx
Mean 41 14 10 38 18 52
Range (10-72) (1-49) (3-23) (4-125) (5-56) (12-127)
VA VentrAssist™LVAD.
HW HeartWare™LVAD.
M Male.
F Female.
LOS (Length of Stay) in days.
ECMO Extra Corporeal Membrane Oxygenation.
ICU Intensive Care Unit.
Htx Heart transplantation.
End points: †=dead, * = on device.
^^ patient no 6 and 9 from the HeartWare LVAD study was excluded as patient had HW BIVAD.
**Mean cost for ECMO is only for the patients with ECMO.
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were $ 63, 963 (range 9, 738- 187, 097). The major cost
drivers in this phase were personnel cost (43%) and
ECMO-procedure cost (42%). Two patients had three
and seven days on ECMO before the LVAD implant-
ation. Five patients were on IABP in Medical intensive
care unit (MICU). The mean LOS in the pre-LVAD
phase was 14 days (range 0- 36). In the LVAD-phase
mean costs were $ 346, 403 (range 273, 498- 425, 843).
The major cost drivers were device costs (58%) and
personnel cost (27%). The mean LOS for the LVAD
phase was 35 days (range 19- 57). In the post-LVAD
phase mean costs were $ 2, 819 (range 1, 310- 9, 724).
Device costs were $ 121,280 for VentrAssist™ LVAD and
$ 200,913 for HeartWare™.
Of the two different specifications the ones without a
dummy variable describing type of LVAD perform best
for both dependent variables. Of the analyses of the two
dependent variables the one where device costs are
excluded have the best performance (Adjusted r R2).
The estimates from the regression analysis of total costs
excluding device costs indicated that costs were falling
as the number of treated patients increased (Table 2,
Figure 2). The estimate from the trend variable was -
$ 14,096 (CI -3,842 to -24,349, p < 0.01) indicating that
for each additional patient, total LVAD-costs excluding
device costs, were reduced on average.
A number of adverse effects were observed (Table 3).
The most common device related adverse effects within
30 days were four systemic or deep infections and one
patient had percutaneous lead exit site infection. None
of the patients had device malfunction necessitating
removal or change of parts of the systems.
Discussion
There have been attempts to analyze true hospital cost of
LVAD [9-11]. However to our knowledge there are no
studies where costs of two different devices have been in
dept analyzed. In this study we have explored the effect of
accumulated clinical experience. We have documented
costs related to the LVAD procedure which is a necessary
Table 2 Average patient costs ($) per LVAD phase, cost drivers per phase and average total costs ($) for 20
VentrAssist™ LVAD and 9 HW HeartWare™LVAD
Total costs in $ (range)
20 VentrAssist™LVAD 9 HeartWare
TMLVADs
Pre-LVAD phase 186, 467 (6, 000- 586, 421) 63, 963 (9,738- 187, 097)
Cost drivers %
Personnel 63 43
ECMO procedure 23 42
Blood 9 6
Drugs 1 1
Laboratory/radiology 4 8
Sum 100 100
LVAD phase 378, 450 (41, 957- 696, 483) 346, 403 (273, 498- 425, 843)
Cost drivers %
Personnel 52 27
Device costs 32 58
Operating room cost 11 10
Blood 1 2
Drugs 1 1
Laboratory/radiology 3 2
Sum 100 100
Post- LVAD phase 18,093 (8,729,- 59, 345) 2, 819 (1,310- 9,724)
Cost drivers %
Day hospital stays (under 5 hours) 69 0
In-hospital stays 27 55
External consultations 2 22
Internal consultations 2 23
Sum 100 100
Mean total costs 585, 513 413 185
Range (132, 640- 1 247, 299) (314, 540- 622, 664)
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step to evaluate the procedure’s cost efficiency. Further,
this analysis focuses on the existing reimbursement issues.
The mean total cost for the LVAD procedure is largely
driven by the pre-LVAD phase where significant personnel
resources were used commonly related to ICU treatments.
In the LVAD phase the major part of cost was related to
device cost. However, as different LVADs systems in pipe-
line are offered by different manufacturing companies and
indications will be expanded to a more widespread use, it
is likely that device costs will be reduced in the future.
It is worthwhile to mention that total cost for all three
phases was almost 30% lower (from $ 585, 513 to $ 413,
185) in the second era using the new device for intra-
pericardial placement (HeartWare™LVAD) with even
higher device cost compare to (VentrAssist™LVAD). On
the other hand in first period most instances patients also
required more extensive surgery. The total mean cost for
pre LVAD phase of the first 20 VentrAssist™LVADs to
nine HeartWare™LVADs the total mean cost for Heart-
Ware™LVAD was 62% lower (186, 467 to 63, 963), indi-
cating a more aggressive attitude to LVAD implantation
than in the first study period.
The unit costs of personnel resources used in LVAD
phase with the first 20 patients were 20% higher than in the
second period, while the device cost for HeartWare™LVAD
was 26% higher compared to VentrAssist™LVAD. Thus, for
the LVAD phase taken together the reduction in total costs
was only 9% (from $ 378, 450 to $ 346, 403). The total
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Figure 1 Costs ($) per patient per LVAD phase and cost drivers for 20 VentrAssist™ LVAD and 9 HW HeartWare™LVAD.
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mean cost for post LVAD phase of the first 20 VentrAs-
sist™LVADs to nine HeartWare™LVADs was considerably
higher and can be explained by fact that first study period
patients post LVAD phase check up was regularly at hos-
pital. In second study period this function was allocated to
local hospital.
The falling trend was also observed for the total in-
hospital mean LOS. The total LOS for the pre LVAD
and LVAD phase in the second period was lower than
compared to the first period.
Although the results from the regression analyses
should be regarded as indicative as the number of units
are low, the gradually declining costs were confirmed.
The marginal cost reduction was $ 14, 096 or 3.7% per
patients calculated on the basis of total hospital costs ex-
cluding device costs. Within the range of this analysis
there was no indication that the cost reductions were
decreasing. The results should be considered in the light
of the fact that by the first patients our institution was
trying to establish a new treatment program. Costs at
this stage were associated with low volume and high use
of manpower. The higher cost among the first patients
can be explained by longer LOS and more invasive treat-
ment. These findings are also documented by other
authors [12,13]. As the number of patients increased the
department experienced learning effect from better lo-
gistics, selection and management of patients [14-17].
There are no studies that are exactly comparable in
the literature. To our knowledge this is the first pub-
lished study with an evaluation of the total patient cost
including cost for pre-LVAD, LVAD and post LVAD
period up to one year follow-up for two different con-
secutively used devices in a single institution program.
Innovative medical technology has impact on costs,
but may with careful introduction improve health out-
comes and quality of life substantially. First, when a
technology/treatment becomes less expensive and safer
fewer complications, meaningful improvements in qual-
ity of life, more patients may decide that a treatment is
worth the risks and unpleasantness [18].
Efficacy and safety of LVAD have been reported in sev-
eral studies [19,20]. However, there is no strong evidence
that LVAD is a cost-effective choice of treatment for
bridge to transplant patient group [21,22]. A recent study
from Roger JG [23] at el indicate that LVADs appear bene-
ficial, improve survival and quality of life but also that the
cost per quality adjusted life year was high. Although
LVADs may appear clinically effective as an alternative to
HTx it is unlikely they will be cost-effective unless a sig-
nificant cost decrease and a reduction in complications
and a quality of life, will be proven. Further research in
our institution should also address the cost effectiveness
of the LVAD program in the long term as a bridge to Htx
and as well for chronic LVAD patients.
Assuming that our cost estimates are correct, the dis-
crepancy between cost and reimbursement illustrates
one of the basic problems by the price setting in the
DRG-system; costly innovations and implementations
are not reflected in the prices of the system at early
stages [24]. At best 3-4 years are spent to recalculate the
cost weights of the system after an innovation is imple-
mented. However, after our previous study documenta-
tion of cost and DRG reimbursement policy maker
agreed upon that there was a need to allocate a specific
DRG for LVADs in Norway. For 2012 (Activity based fi-
nancing 2012) there will be a share of DRG reimburse-
ment for LVADs [25]. However, this study also raises
another discussion. Since standard reimbursement can-
not cover the costs of the innovative phases in hospital
treatments specific grants to innovation processes
should be considered.
Conclusions
The hospital costs per patients were falling as the num-
bers of LVADs were increasing. The higher cost among
the first patients can be explained by longer LOS and
more invasive treatment in the pre-LVAD phase. As the
number of patients increased the department experi-
enced learning effect from better logistics, selection and
management of patients. This reduced total costs ex-
cluding device costs by approximately $ 14, 000 or 3.6%
per each additionally treated patient.
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Abbreviations
LVAD: Left ventricular assist device; VA: VentrAssist™LVAD;
HW: HeartWare™LVAD; LOS: (Length of Stay); ECMO: Extra Corporeal
Table 3 Adverse events
Adverse events ≤30 days events >30 days events
VA HW VA HW
Local Infection 1 1 3 2
Percutaneous lead exit site 1 4
Pump pocket 1 2 0
Systemic (sepsis) 1 0
Neurological event 3 2 2 0
Hemorrhagic 1 1
Embolic 2 1 2 0
Resolved (no disability) 2
Minor disability 3
Bleeding in need of surgery 1 0 0
System malfunction affecting therapy 0 0 0 0
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Membrane Oxygenation; ICU: Intensive Care Unit; Htx: Heart transplantation;
MICU: Medical intensive care unit; TICU: Thorax intensive care unit.
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